关注
Camillo Porta
Camillo Porta
Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri
在 icsmaugeri.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Sorafenib in advanced hepatocellular carcinoma
JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
150242008
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ...
New England Journal of Medicine 378 (14), 1277-1290, 2018
40842018
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ...
The Lancet 372 (9637), 449-456, 2008
37232008
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger, N Rioux-Leclercq, A Bex, V Khoo, ...
Annals of Oncology 30 (5), 706-720, 2019
15982019
Targeting PI3K/Akt/mTOR signaling in cancer
C Porta, C Paglino, A Mosca
Frontiers in oncology 4, 64, 2014
15602014
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ...
Cancer 116 (18), 4256-4265, 2010
15162010
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ...
New England Journal of Medicine 384 (14), 1289-1300, 2021
12692021
Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ...
New England Journal of Medicine 384 (9), 829-841, 2021
12652021
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ...
Journal of hepatology 57 (4), 821-829, 2012
9372012
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...
The Lancet 393 (10189), 2404-2415, 2019
9212019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised …
RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ...
The Lancet Oncology 20 (10), 1370-1385, 2019
7252019
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ...
The lancet oncology 10 (8), 757-763, 2009
7102009
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
A Santoro, L Rimassa, I Borbath, B Daniele, S Salvagni, JL Van Laethem, ...
The lancet oncology 14 (1), 55-63, 2013
6582013
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
B Escudier, C Porta, P Bono, T Powles, T Eisen, CN Sternberg, ...
4782014
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ...
ESMO open 5 (6), e001079, 2020
4692020
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises
F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ...
Cancer treatment reviews 41 (2), 114-121, 2015
4592015
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger, F Algaba, JJ Patard, V Khoo, T Eisen, ...
Annals of oncology 25, iii49-iii56, 2014
4582014
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
3982020
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, T Eisen, C Porta, JJ Patard, V Khoo, F Algaba, P Mulders, ...
Annals of oncology 23, vii65-vii71, 2012
3902012
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
L Rimassa, E Assenat, M Peck-Radosavljevic, M Pracht, V Zagonel, ...
The Lancet Oncology 19 (5), 682-693, 2018
3472018
系统目前无法执行此操作,请稍后再试。
文章 1–20